ReviewCureus2026
Narrative Review of Body-First Versus Brain-First Prodromal Neuropsychiatric Symptoms in Parkinson's Disease.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a multisystem neurodegenerative disorder in which nonmotor symptoms often precede classical motor manifestations by years. Neuropsychiatric symptoms such as REM sleep behavior disorder (RBD), depression, anxiety, apathy, and mild cognitive impairment are increasingly recognized as clinically meaningful prodromal features, yet they remain underrecognized in routine practice. This narrative review summarizes literature identified through PubMed, Scopus, and Google Scholar between 2003 and 2025 using terms related to PD, prodromal symptoms, neuropsychiatric symptoms, alpha-synuclein, and body-first versus brain-first disease. Priority was given to review articles, original studies, clinical trials, Movement Disorder Society prodromal criteria, and foundational neuropathological models. Current evidence supports a dual pathway model of PD progression. In the body-first phenotype, pathology may begin in the peripheral autonomic or enteric nervous system and ascend through the brainstem, where RBD and autonomic dysfunction are prominent early markers. In the brain-first phenotype, pathology is proposed to arise in olfactory or limbic regions, where hyposmia, anxiety, and depression may precede motor disease. Prodromal neuropsychiatric symptoms are among the earliest clinically detectable features of PD. Interpreting these symptoms within the body first versus brain first framework may improve risk stratification, earlier recognition, and selection of candidates for biomarker-driven and disease-modifying studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.